Associations between metabolomic compounds and incident heart failure among African Americans: The ARIC study

American Journal of Epidemiology

Volumn 178, Issue 4, 2013, Pages 534-542

  Zheng, Yan ^a   Yu, Bing ^a   Alexander, Danny ^c   Manolio, Teri A ^b   Aguilar, David ^d   Coresh, Josef ^e   Heiss, Gerardo ^f   Boerwinkle, Eric ^a   Nettleton, Jennifer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c METABOLON INC   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f IL   (United States)

Author keywords

heart failure; metabolomics; risk factors

Indexed keywords

ALANINE DERIVATIVE; CRESOL; DIPEPTIDE; ERYTHRITOL; GLUCOSE; GLUTAMINE DERIVATIVE; HYDROXYPROLINE; N ACETYLALANINE; P CRESOL SULFATE; PHENYLACETYLGLUTAMINE; PROLYLHYDROXYPROLINE; PYROGLUTAMINE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; AMINO ACID; BASELINE SURVEY; BIOMARKER; CARDIOVASCULAR DISEASE; HEALTH RISK; HOSPITAL SECTOR; METABOLISM; METABOLITE; REGRESSION ANALYSIS; RISK FACTOR; SERUM;

ADULT; AFRICAN AMERICAN; AMINO ACID METABOLISM; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS;

HEART FAILURE; METABOLOMICS; RISK FACTORS;

AFRICAN AMERICANS; AGE DISTRIBUTION; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; METABOLOMICS; MIDDLE AGED; MISSISSIPPI; OBESITY; PROPORTIONAL HAZARDS MODELS; SEDENTARY LIFESTYLE;

JACKSON COUNTY [MISSISSIPPI]; MISSISSIPPI; UNITED STATES;

EID: 84881600364     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt004     Document Type: Article

References (55)

1. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol. 2008;51(18):1775-1783.
2. Martins H, Pedro N, Castellano M, et al. Cardio-renal syndrome: the challenge in heart failure treatment [in Portuguese]. Acta Med Port. 2011;24(2):285-292.
3. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000; 35(6):1628-1637.
4. Wang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors in relation to heart failure among Finnish men and women. Circ Heart Fail. 2011;4(5):607-612.
5. Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237-244.
6. Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58(1):47-55.
7. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(3 Pt 1):951-957.
8. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20): 1557-1562.
9. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 1989;10(7):647-656.
10. Ingelsson E, Arnlov J, Sundstrom J, et al. Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005;46(11): 2054-2060.
11. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305-313.
12. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 suppl A):6A-13A.
13. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol. 1974;34(1):29-34.
14. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4): 448-453.
15. Tuunanen H, Ukkonen H, Knuuti J. Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep. 2008;10(2):142-148.
16. Obrzut S, Tiongson J, Jamshidi N, et al. Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy. J Cardiovasc Transl Res. 2010;3(6):643-651.
17. Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. Circulation. 2005;111(10):1233-1241.
18. Clark LT. Issues in minority health: atherosclerosis and coronary heart disease in African Americans. Med Clin North Am. 2005;89(5):977-1001.
19. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687-702.
20. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36(5):936-942.
21. Din-Dzietham R, Liao D, Diez-Roux A, et al. Association of educational achievement with pulsatile arterial diameter change of the common carotid artery: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1992. Am J Epidemiol. 2000;152(7):617-627.
22. Sharrett AR, Hubbard LD, Cooper LS, et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1999;150(3): 263-270.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(1 suppl): 62S-69S.
24. Casale PN, Devereux RB, Alonso DR, et al. Improved sexspecific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75(3):565-572.
25. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
26. Perkel JM. Metabolomics. South San Francisco, CA: Biocompare; 2011. (http://www.biocompare.com/Articles/EditorialArticle/1275/Metabolomics.html). (Accessed January 4, 2012).
27. Suhre K, Meisinger C, Doring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5(11):e13953.
28. Floegel A, Drogan D,Wang-Sattler R, et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One. 2011;6(6):e21103.
29. Eriksson H, Caidahl K, Larsson B, et al. Cardiac and pulmonary causes of dyspnoea-validation of a scoring test for clinical-epidemiological use: the study of men born in 1913. Eur Heart J. 1987;8(9):1007-1014.
30. Wilhelmsen L, Eriksson H, Svardsudd K, et al. Improving the detection and diagnosis of congestive heart failure. Eur Heart J. 1989;10(C suppl):13S-18S.
31. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2008;101(7):1016-1022.
32. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008;1(2):125-133.
33. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123(13):1367-1376.
34. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
35. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham risk score Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract. 2011;119(2):c171-c177; discussion c7-c8.
36. Rutkowski B, Rutkowski P, Slominska E, et al. Cellular toxicity of nicotinamide metabolites. J Ren Nutr. 2012;22(1):95-97.
37. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4(7):1275-1283.
38. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980; 67(1):145-153.
39. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16(22):2529-2542.
40. Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010;5(7):1182-1189.
41. Winchester JF, Hostetter TH, Meyer TW. p-Cresol sulfate: further understanding of its cardiovascular disease potential in CKD. Am J Kidney Dis. 2009;54(5):792-794.
42. Mayr M. Metabolomics: Ready for the prime time Circ Cardiovasc Genet. 2008;1(1):58-65.
43. Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156(5):965-974.
44. Kazemian P, Kazemi-Bajestani SM, Alherbish A, et al. The use of omega-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc Drugs Ther. 2012;26(4):311-320.
45. Fu SL, Dean RT. Structural characterization of the products of hydroxyl-radical damage to leucine and their detection on proteins. Biochem J. 1997;324(Pt 1):41-48.
46. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J. 2003;24(24):2161-2163.
47. Dalla Libera L, Ravara B, Gobbo V, et al. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol. 2005; 38(5):803-807.
48. Tangney CC, Shekelle RB, RaynorW, et al. Intra-and interindividual variation in measurements of beta-carotene, retinol, and tocopherols in diet and plasma. Am J Clin Nutr. 1987;45(4):764-769.
49. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. 2009;32(9):1678-1683.
50. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 2008;52(2):117-123.
51. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289(19):2560-2572.
52. Yancy CW. Heart failure in African Americans. Am J Cardiol. 2005;96(7B):3i-12i.
53. Schoots AC, Dijkstra JB, Ringoir SM, et al. Are the classical markers sufficient to describe uremic solute accumulation in dialyzed patients Hippurates reconsidered. Clin Chem. 1988;34(6):1022-1029.
54. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189-218.
55. Smith NL, Felix JF, Morrison AC, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective metaanalysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3(3):256-266.